Increasing number of IV TXA doses further improves efficacy without increasing VTE risk in THA
Increasing number of IV TXA doses further improves efficacy without increasing VTE risk in THA
Multiple-Dose Intravenous Tranexamic Acid Further Reduces Hidden Blood Loss After Total Hip Arthroplasty: A Randomized Controlled Trial
J Arthroplasty. 2018 Sep;33(9):2940-2945. doi: 10.1016/j.arth.2018.04.024Synopsis
150 patients scheduled for total hip arthroplasty and administered an intravenous dose of tranexamic acid prior to incision were randomized to either an additional 2, 3, or 4 IV TXA doses after 3 hour intervals thereafter. Patients were assessed for hidden blood loss, total blood loss, intraoperative blood loss, hemoglobin drop, transfusion rate, length of hospital stay, and incidence of thromboem...
                To view the full content, login to your account,
or start your 30-day FREE Trial today.
            
            FREE TRIAL
            LOGIN
            Forgot Password?
    Explore some of our unlocked ACE Reports below!
 
                Learn about our AI Driven 
 High Impact Search Feature
     
    Our AI driven High Impact metric calculates the impact an article will have by considering both the publishing journal and the content of the article itself. Built using the latest advances in natural language processing, OE High Impact predicts an article’s future number of citations better than impact factor alone.
Continue 
                     
                 
                                                         
                                                         
                                                         
                                                         
                                                         
                                                         
                                                         
                                                         
                                                         
                                                         
                                                         
                                                         
                                                         
                                                         LOGIN
                                    LOGIN
                                 
             
                        
Join the Conversation
Please Login or Join to leave comments.